Bio-Rad Labs (BIO) Misses Q4 EPS by 20c; offers outlook

Bio-Rad Labs (NYSE: BIO) reported Q4 EPS of $2.51, $0.20 worse than the analyst estimate of $2.71. Revenue for the quarter came in at $693.2 million versus the consensus estimate of $692.96 million.

Full-Year 2026 Financial Outlook

Bio-Rad is providing its financial outlook for the full-year 2026. The Company currently expects non-GAAP, currency neutral revenue growth of approximately 0.5 to 1.5 percent and an estimated non-GAAP operating margin of approximately 12.0 to 12.5 percent.

For earnings history and earnings-related data on Bio-Rad Labs (BIO) click here.

You May Also Be Interested In

• NeoVolta Inc. (NEOV) Misses Q3 EPS by 17c
• First Merchants prices $100M subordinated notes offering at 6.75%
• Visa deposits $405M into U.S. litigation escrow, adjusting stock rates